Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

314
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
314
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Introduction to Epidemiology01:26

Introduction to Epidemiology

1.5K
Epidemiology, known as the cornerstone of public health, involves studying the distribution and determinants of health-related events in defined populations and applying these insights to control health issues. This is essential for understanding how diseases spread, identifying populations at greater risk, and implementing measures to control or prevent outbreaks. Epidemiology addresses not only infectious diseases but also non-communicable conditions like cancer and cardiovascular disease,...
1.5K
Hazard Ratio01:12

Hazard Ratio

459
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
459
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

735
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
735

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative.

Clinical pharmacology and therapeutics·2026
Same author

The evolving global landscape of first-in-class oncology drug innovation.

Signal transduction and targeted therapy·2026
Same author

Clinically Meaningful, Patient-Centered Endpoints for Real-World Evidence Generation in Breast Cancer: Perspectives from the Multidisciplinary TRIUMPH Initiative.

Advances in therapy·2026
Same author

From Image-Guided Surgery to Computer-Assisted Real-Time Diagnosis with Hyperspectral and Multispectral Imaging: A Systematic Review in Gynecologic Oncology.

Diagnostics (Basel, Switzerland)·2026
Same author

Surgeons' awareness, expectations, and involvement with artificial intelligence: a survey pre and post the GPT era.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2025
Same author

Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank.

Advances in therapy·2025

Related Experiment Video

Updated: Dec 15, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.0K

Bridging the Gap Between RCTs and RWE Through Endpoint Selection.

Robert J LoCasale1, Chris L Pashos2, Ben Gutierrez3

  • 1Real World Evidence, Sanofi, Bridgewater, NJ, USA.

Therapeutic Innovation & Regulatory Science
|July 8, 2020
PubMed
Summary

Industry experts explore integrating real-world evidence (RWE) into randomized controlled trials (RCTs). They compare clinical trial endpoints with real-world data to find ways to use RWE more effectively in research settings.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K

Related Experiment Videos

Last Updated: Dec 15, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.0K

Area of Science:

  • Health Economics and Outcomes Research
  • Clinical Trial Design
  • Real-World Evidence

Background:

  • Industry experts convened as the RWE Leadership Forum to address challenges and opportunities in real-world data (RWD) and real-world evidence (RWE).
  • A significant disconnect exists between traditional randomized controlled trials (RCTs) and the application of RWE in clinical research.
  • The forum aims to foster a unified voice to bridge this gap and promote RWE utilization within the RCT framework.

Purpose of the Study:

  • To evaluate the value of integrating RWE into the RCT environment.
  • To explore the potential for using RWE endpoints within the established RCT structure.
  • To identify pathways and address gaps for assimilating RWE into RCTs.

Main Methods:

  • Analysis of existing RCT endpoints, focusing on clinical relevance and direct patient benefit.
  • Comparison of RCT endpoints with their real-world data (RWD) counterparts.
  • Expert commentary and discussion from industry leaders on bridging the RWE and RCT disconnect.

Main Results:

  • Exploration of various axes for comparing RCT and RWE endpoints.
  • Identification of potential areas for RWE assimilation into RCTs.
  • Discussion on the clinical relevance and patient benefit measures of different endpoint types.

Conclusions:

  • Bridging the disconnect between RCTs and RWE is crucial for advancing clinical research.
  • RWE offers valuable insights that can potentially enhance RCT design and outcomes.
  • Further investigation is needed to establish clear methodologies for integrating RWE endpoints into RCTs to improve patient benefit assessment.